Arbutus Biopharma (ABUS) Non Operating Income (2015 - 2026)

Arbutus Biopharma has disclosed Non Operating Income across 12 years of filings, most recently posting $787000.0 for Q1 2026.

• Non Operating Income for Q1 2026 came in at $787000.0, down 32.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.3 million (down 29.77% YoY), and the FY2025 annual result was $4.7 million, down 27.19% from the prior year.
• Non Operating Income came in at $787000.0 for Q1 2026 at Arbutus Biopharma, down from $1.5 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $1.8 million in Q2 2024 to a low of -$347000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $1.2 million (2025), against an average of $1.0 million.
• Across the five-year window, Non Operating Income jumped 1655.42% in 2023 and tumbled 46.78% in 2025, its largest moves.
• Arbutus Biopharma's Non Operating Income stood at $630000.0 in 2022, then surged by 127.78% to $1.4 million in 2023, then fell by 2.37% to $1.4 million in 2024, then climbed by 9.49% to $1.5 million in 2025, then sank by 48.7% to $787000.0 in 2026.
• The last three Non Operating Income figures came in at $787000.0 (Q1 2026), $1.5 million (Q4 2025), and $917000.0 (Q3 2025), per Business Quant data.